The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 13 April 2026•Updated 14 April 2026•

1 min read

ANI Pharmaceuticals Launches Generic Carbatrol in US Market

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1ANI Pharmaceuticals launched Carbamazepine Extended-Release Capsules, a generic version of Carbatrol.

about 2 months ago

Version History

Version 1about 2 months ago

What changed: Added the official launch date (April 13, 2026), identified IQVIA as the market data source, and included the company's headquarters and Nasdaq ticker.

ANI Pharmaceuticals (Nasdaq: ANIP), headquartered in Princeton, N.J., officially launched its Carbamazepine Extended-Release Capsules on April 13, 2026. As a generic equivalent to Carbatrol, the product is available in 100 mg, 200 mg, and 300 mg strengths to treat epilepsy and bipolar disorder. This launch targets a U.S. market segment with annual sales of approximately $65 million, according to data from IQVIA. By entering this niche market, ANI Pharmaceuticals aims to capitalize on a segment characterized by limited competition. The move aligns with the company's strategy to expand its generics portfolio and drive sustainable revenue growth. Analysts expect a positive contribution to financial results, though the impact remains moderate relative to the total market size.